multi-factorial modifications to the liver-specific promoter module, hF8 transgene, synthetic polyadenylation signal and vector backbone sequence. Forward-Looking Statements This press release contains forward-looking statements based on Sangamo's current expectations. Jetzt neu: für Sangamo Therapeutics ist der Dividenden-Chartvergleich verfügbar: Der Dividenden-Chartvergleich zeigt die Rendite inklusive der Ausschüttungen (Aktienkurs + Dividende, grün) im Vergleich zum Aktienkurs (blau) und so die wirkliche Rendite einer Investition in die Aktie. Yahoo fait partie de Verizon Media. You reached this page when attempting to access https://www.streetinsider.com/Corporate+News/Sangamo+Biosciences+%28SGMO%29+to+Present+Data+From+Several+ZFP+Therapeutic+Programs+at+ASGCT+Meeting/11514295.html from 185.21.103.76 on 2020-10-15 20:03:05 UTC. Der DAX will sich neue Regeln geben – wer steigt in die erste Börsenliga auf? Découvrez comment nous utilisons vos informations dans notre Politique relative à la vie privée et notre Politique relative aux cookies. "kaufen" oder "buy", Hold: Halten-Empfehlungen wie z.B. Pour autoriser Verizon Media et nos partenaires à traiter vos données personnelles, sélectionnez 'J'accepte' ou 'Gérer les paramètres' pour obtenir plus d’informations et pour gérer vos choix. Sangamo's April 2 PR contained the exact same language as Brigit Riley's Hemo A preclinical article in the journal. ", Invited Presentations at Scientific Symposia. My DNA vocabulary is not that great, but I suspect that neither "5' UTR" nor "an N-terminal polypetpide" are covered by the specific language of Rileys Blood article and Sangamo's April 2 press release: I guess its possible that "an N-terminal polypeptide" is part of the "polyadenylation signal". Fuchs interview, https://www.investorvillage.com/uploads/96497/files/rrrrrrrrrr.pdf, 3. //--> MWH, SSM, SS, KM, TW and MCH are full time employees of Sangamo Therapeutics, Inc. Liver-produced α-Gal A is secreted into the bloodstream and taken up by secondary tissues Episomaltherapeutic transgene with liver-specific promoter %Gb3 Remaining Relative to Untreated GLAKO WT KO AAV Dose AAV Dose WT KO AAV Dose AAV Dose WT KO log nmol/hour/mL Improved cDNA Original cDNA Wild … Dow Jones +15 Min. ARM’s new Gene and Gene–Modified Cell Therapy Section (GTS) brings together the leading gene therapy companies and organizations in the U.S. and Europe to advocate for policies and programs to … Dr. Paul Harmatz, a professor at UCSF Benioff Children's Hospital Oakland and a principle investigator for Sangamo's in vivo genome editing clinical programs in mucopolysaccharidosis type I (MPS I) and MPS II, will review clinical data presented earlier this year at the 2019 WORLDSymposium. Copyright © 1998-2020 wallstreet:online AG - Alle Rechte vorbehalten. Forward-looking statements contained in this announcement are made as of this date, and Sangamo undertakes no duty to update such information except as required under applicable law. And that may not even be the best news for Sangamo shareholders. Presumably Biogen is familiar with all of these programs. The goal of these trials is to utilize a ZFN-mediated genome editing strategy to permanently modify patient liver cells through insertion of a corrective transgene at the Albumin locus, following systemic AAV2/6 delivery. These forward-looking statements include, without limitation, references relating to presentation of data from various therapeutic and research programs and the potential of these programs to transform the lives of patients. Sangamo's optimization efforts took much longer so it stands to reason Sangamo will perform better. [CDATA[// >
